Abstracts Archive - Page 1683 of 2425 - ACR Meeting Abstracts

Abstract Number: 3166 • 2015 ACR/ARHP Annual Meeting
Epistatic Interaction of Functional Inflammasome Genetic Variants in Determining the Risk of Gout
Tony R. Merriman¹, Lisa K. Stamp², Nicola Dalbeth³, Ruth Topless⁴, Richard Day⁵, Diluk Kannangara⁵, Kenneth Williams⁵, Matthijs Janssen⁶, Tim Jansen⁷, Leo A. Joosten⁸, Timothy Radstake⁹, Philip L. Riches¹⁰, Anne-Kathrin Tausche¹¹, Frederic Lioté¹², Alex So^13,14 and Cushla McKinney⁴, ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ³Department of Medicine, University of Auckland, Auckland, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵University of New South Wales, Sydney, Australia, ⁶Rheumatology Dept, Ziekenhuis Rijnstate, Arnhem, Netherlands, ⁷P O Box 581, Haarlem, Netherlands, ⁸Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁹Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁰Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom, ¹¹Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ¹²Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹³Service De Rhumatologie, CHUV, Lausanne, Switzerland, ¹⁴Department of Rheumatology, CHUV, Lausanne, Switzerland
Background/Purpose: The acute gout flare results from a localised self-limiting innate immune response to monosodium urate (MSU) crystals deposited in joints in hyperuricaemic individuals. Activation…
Abstract Number: 3167 • 2015 ACR/ARHP Annual Meeting
Association of the Apolipoprotein A1-C3-A4 Gene Cluster with the Risk of Gout: Evidence for a Causal Role in Gout
Tony R. Merriman¹, Amanda Phipps-Green², Ruth Topless², Malcolm D. Smith³, Catherine Hill⁴, Susan Lester⁴, Maureen Rischmueller⁵, Matthijs Janssen⁶, Tim Jansen⁷, Leo A. Joosten⁸, Timothy Radstake⁹, Philip L. Riches¹⁰, Anne-Kathrin Tausche¹¹, Frederic Lioté¹², Alex So^13,14, Andre M. van Rij², Gregory T. Jones¹⁵, Sally McCormick¹⁶, Andrew Harrison², Lisa K. Stamp¹⁷, Nicola Dalbeth¹⁸ and Humaira Rasheed¹⁶, ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Rheumatology, Repatriation General Hospital, Adelaide, Australia, ⁴Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia, ⁵Rheumatology, Queen Elizabeth Hospital, Adelaide, Australia, ⁶Rheumatology Dept, Ziekenhuis Rijnstate, Arnhem, Netherlands, ⁷P O Box 581, Haarlem, Netherlands, ⁸Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁹Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁰Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom, ¹¹Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ¹²Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹³Service De Rhumatologie, CHUV, Lausanne, Switzerland, ¹⁴Department of Rheumatology, CHUV, Lausanne, Switzerland, ¹⁵Surgery, University of Otago, Dunedin, New Zealand, ¹⁶Department of Biochemistry, University of Otago, Dunedin, New Zealand, ¹⁷Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ¹⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Gout is caused by an inflammatory response to monosodium urate (MSU) crystals and is associated with elevated triglyceride and very low density lipoprotein levels.…
Abstract Number: 3168 • 2015 ACR/ARHP Annual Meeting
How Strong Cardiovascular Risk Factor Are Gouty Tophi?
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³ and Zlatimir Kolarov⁴, ¹University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²University Hospital "Alexandrovska", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria, ⁴Clinic of Rheumatology, University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria
Background/Purpose: We have not found a study determining cardiovascular (CV) risk in the different stages of gout. This led us to use a complex multimodal…
Abstract Number: 3169 • 2015 ACR/ARHP Annual Meeting
Diagnostic Value of Ultrasound for the Diagnosis of Gout in a Prospective Cross-Sectional Study
Alexis Ogdie-Beatty¹, William J. Taylor², Tuhina Neogi³, Jaap Fransen⁴, Tim Jansen⁵, H. Ralph Schumacher Jr.⁶ and Nicola Dalbeth⁷, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ³Clinical Epidemiology, BUSM, Boston, MA, ⁴Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁵P O Box 581, Haarlem, Netherlands, ⁶Medicine, Rheumatology, U Penn & VA Med Ctr, Philadelphia, PA, ⁷Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Musculoskeletal ultrasound (US) is a non-invasive option for diagnosing gout. However, little is known about the test characteristics of US for the diagnosis of…
Abstract Number: 3170 • 2015 ACR/ARHP Annual Meeting
Peripheral Osteoblastogenesis in Rheumatoid Arthritis Is Enhanced after TNF Blocker Treatment, Irrespective of Systemic Inflammation
Mie Jin Lim¹, Won Park², Seong-Ryul Kwon², Kyong-Hee Jung² and Min Jung Son³, ¹Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Inha University Hospital, Incheon, South Korea
Background/Purpose: We investigated osteoclastogenesis and osteoblastogenesis in peripheral blood before and 6 months after TNF blocker treatment in seropositive RA patients. Methods: Seventeen seropositive…
Abstract Number: 3171 • 2015 ACR/ARHP Annual Meeting
Combination Therapy with Denosumab and Biologic DMARD Associated with Higher Risk of Serious Infections Compared to Denosumab Alone and Biologic DMARD Alone
Ivana Parody¹, Luis Arias-Urdaneta², Ricardo Garcia Alemany² and Carlos Sesin², ¹Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL, ²Vanguard Rheumatology Partners, Miami Beach, FL
Background/Purpose: Patients with RA and other rheumatologic disorders are at increased risk for osteoporotic fractures. Biologic DMARDs are an important treatment option for these patients.…
Abstract Number: 3172 • 2015 ACR/ARHP Annual Meeting
Effect of Anti Citrullinated Protein Antibodies on Periarticular and Systemic Bone Mass in Early Arthritis Patients
Irene Llorente Cubas*¹, Leticia Merino-Meléndez², Ana M. Ortiz Garcia², Eugenio Escolano³, Teresa Velasco¹, Elena García², Esther Vicente-Rabaneda², Alberto Garcia-Vadillo⁴, Rosario Garcia-Vicuña⁴, Isidoro González-Alvaro*² and Santos Castañeda*², ¹Rheumatology, H.U La Princesa, Madrid, Spain, ²Rheumatology, H.U. La Princesa, Madrid, Spain, ³Radiology Department, H.U La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Recently it has been described that anti citrullinated protein antibodies (ACPA) can induce differentatiomn and activation of osteoclasts even before arthritis onset (1,2). The…
Abstract Number: 3173 • 2015 ACR/ARHP Annual Meeting
Premature Mortality Due to Fractures in a Population-Based Prospective Cohort Study of 238,673 Older Women and Men
Lyn March¹, Weiwen Chen², Judy M Simpson³, Fiona Blyth⁴ and Jacqueline Center², ¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ²Endocrinology, Osteoporosis & Bone Biology Garvan Institute of Medical Research, St Vincent's Clinical School, UNSW, Darlinghurst, Australia, ³Statistics, University of Sydney School of Public Health, Sydney, Australia, ⁴Concord Clinical School University of Sydney and Sax Institute, Sydney, Australia
Background/Purpose: Osteoporotic (OP) fractures and falls are a growing global problem as the population ages. One third of all falls related deaths are attributable to…
Abstract Number: 3174 • 2015 ACR/ARHP Annual Meeting
Vitamin D Binding Protein and Tenofovir-Associated Bone Loss Among Individuals with HIV
Evelyn Hsieh^1,2, Liana Fraenkel¹, Weibo Xia³, Yang Han², Michael Yin⁴, Karl Insogna⁵, Ting Zhu² and Taisheng Li², ¹Section of Rheumatology, Yale School of Medicine, New Haven, CT, ²Department of Infectious Diseases, Peking Union Medical College Hospital, Beijing, China, ³Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China, ⁴Division of Infectious Diseases, Columbia University Medical Center, New York, NY, ⁵Section of Endocrinology, Yale School of Medicine, New Haven, CT
Background/Purpose: Antiretroviral regimens containing tenofovir disoproxil fumarate (TDF) have been associated with decreases in bone mineral density, and elevations in bone turnover markers (BTM) and…
Abstract Number: 3175 • 2015 ACR/ARHP Annual Meeting
Strength at the Lumbar Spine and Hip Improves with Romosozumab Compared with Teriparatide in Postmenopausal Women with Low Bone Mass
TM Keaveny¹, DB Crittenden², MA Bolognese³, HK Genant⁴, K Engelke⁵, B Oliveri⁶, JP Brown⁷, BL Langdahl⁸, YC Yang², A Grauer² and C Libanati⁹, ¹UC Berkeley, Berkeley and O.N. Diagnostics, Berkeley, CA, ²Amgen Inc., Thousand Oaks, CA, ³The Bethesda Health Research Center, Bethesda, MD, ⁴UCSF & Synarc Inc., San Francisco, CA, ⁵Synarc Germany, Hamburg, Germany, ⁶Hospital de Clínicas, INIGEM, Buenos Aires, Argentina, ⁷Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada, ⁸Aarhus University Hospital, Aarhus, Denmark, ⁹UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab is a bone-forming agent that inhibits sclerostin. In a phase 2 study (NCT00896532), 12 months of romosozumab increased DXA bone mineral density (BMD)…
Abstract Number: 3176 • 2015 ACR/ARHP Annual Meeting
New Prospects for Interpreting Bony Depressions in Juvenile Idiopathic Arthritis: A Novel MRI Computer-Assisted Technique for Detection of Erosive Progression
Pieter van Dijkhuizen^1,2, Carlotta Covizzi¹, Andrea Schiappacasse³, Michela Moraldo⁴, Matteo Santoro⁵, Francesca Magnaguagno⁶, Gianmichele Magnano⁷, Alberto Martini^1,4 and Clara Malattia^1,4, ¹Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy, ²UMC Utrecht, Wilhelmina Children’s Hospital, Pediatric rheumatology, Utrecht, Netherlands, ³DIBRIS Università degli studi di Genova, Genova, Italy, ⁴DINOGMI Università degli studi di Genova, Genova, Italy, ⁵Camelot Biomedical Systems, Genova, Italy, ⁶Istituto G Gaslini, UO Radiologia Pediatrica, Genoa, Italy, ⁷Istituto G Gaslini, UO Radiologia Pediatrica, Genova, Italy
Background/Purpose: Structural damage is the main disease outcome to be avoided in JIA. The gold standard to assess joint damage in JIA is X-ray, which…
Abstract Number: 3177 • 2015 ACR/ARHP Annual Meeting
Whole-Body MRI: A Valuable Diagnostic Tool for the Assessment of Disease Damage in Juvenile Dermatomyositis
Clara Malattia¹, Agnese Beltramo¹, Isabella Buffoni¹, Annalisa Madeo¹, Francesca Magnaguagno², Stefania Viola¹ and Alberto Martini^1,3, ¹Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy, ²Istituto G Gaslini, UO Radiologia Pediatrica, Genoa, Italy, ³Pediatria, Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy
Background/Purpose: Although the prognosis of JDM has significantly improved during the past decade, some patients still experience persistent active disease, which potentially leads to irreversible…
Abstract Number: 3178 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Uveitis Associated to Juvenile Idiopathic Arthritis. Multicenter Study of 13 Cases
Montserrat Santos-Gómez¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Inmaculada Calvo², Marina Mesquida³, Alfredo Adan³, M. Victoria Hernández⁴, Olga Maiz Alonso⁵, Antonio Atanes-Sandoval⁶, Beatriz Bravo⁷, Consuelo Modesto⁸, Gisela Diaz Soriano⁹, Javier Loricera¹, Leyre Riancho-Zarrabeitia¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital La Fe, Valencia, Spain, ³Ophthalmology, Hospital Clinic, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Rheumatology, Donostia University Hospital, Donostia, Spain, ⁶Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ⁷Rheumatology, Hospital Universitario HUVN, Granada, Spain, ⁸Rheumatology, Hospital HSLL, Palma de Mallorca, Spain, ⁹Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain
Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory uveitis associated to juvenile idiopathic arthritis (JiA).Methods: Multicenter study of uveitis related to JiA…
Abstract Number: 3179 • 2015 ACR/ARHP Annual Meeting
Diagnosing Childhood Small Vessel CNS Vasculitis
Marinka Twilt¹, Maryam Nabavi Nouri², Pascal N. Tyrrell³, Anastasia Dropol¹, Shehla Sheikh⁴, Cynthia Hawkins⁵ and Susanne Benseler^6,7, ¹Rheumatology, Alberta Children's Hospital, Calgary, AB, Canada, ²Neurology, The Hospital for Sick Childern, Toronto, ON, Canada, ³Department of Medical Imaging, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Alberta Children's Hospital Research Institute/University of Calgary, Calgary, AB, Canada, ⁷Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada
Background/Purpose: Childhood primary small vessel CNS vasculitis (SVcPACNS) is an increasingly recognized inflammatory brain disease with high morbidity and mortality mandating an elective brain biopsy…
Abstract Number: 3180 • 2015 ACR/ARHP Annual Meeting
Mesenchymal Stromal Cell Treatment in Juvenile Idiopathic Arthritis: A Pilot Study
Joost Swart¹, Nico Wulffraat², Berent J. Prakken³, Ineke Slaper-Cortenbach⁴ and Caroline Lindemans⁵, ¹PO Box 85090, UMC Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center, Utrecht, Netherlands, ⁴Cell Therapy Facility, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pediatric Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a frequent childhood disease with a prevalence of 1 per 1000 children. The introduction of the biological agents including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].